|Day Low/High||0.09 / 0.09|
|52 Wk Low/High||0.02 / 0.16|
ErgoD2 may be an important supplement to existing treatment for individuals suffering from chronic kidney disease (CKD), as an aid in the dietary management of the disease.
CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") and its Clinical Research Organization (CRO) Ergomed plc (AIM:ERGO) today announced that they have expanded their co-development agreement with...
Expanded GROHÂ® line to be launched at Intercoiffure America/Canada May 19th & 20th